Aileron Therapeutics, Inc. (NASDAQ:ALRN) – Equities research analysts at William Blair issued their Q1 2018 earnings estimates for Aileron Therapeutics in a report issued on Friday. William Blair analyst Y. Xu expects that the company will post earnings per share of ($0.49) for the quarter. William Blair currently has a “Outperform” rating on the stock.

Several other equities research analysts also recently weighed in on the company. Canaccord Genuity reissued a “buy” rating and issued a $19.00 price target on shares of Aileron Therapeutics in a report on Friday, August 11th. Bank of America Corporation assumed coverage on Aileron Therapeutics in a report on Monday, July 24th. They issued a “buy” rating and a $19.00 price target for the company. Finally, Jefferies Group LLC started coverage on Aileron Therapeutics in a report on Monday, July 24th. They issued a “buy” rating and a $20.00 price target for the company.

TRADEMARK VIOLATION WARNING: “Aileron Therapeutics, Inc. (ALRN) to Post Q1 2018 Earnings of ($0.49) Per Share, William Blair Forecasts” was first published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this article on another website, it was illegally copied and reposted in violation of US & international copyright and trademark law. The original version of this article can be accessed at https://theolympiareport.com/2017/11/15/aileron-therapeutics-inc-alrn-to-post-q1-2018-earnings-of-0-49-per-share-william-blair-forecasts.html.

Shares of Aileron Therapeutics (ALRN) traded down $0.12 during midday trading on Monday, reaching $11.66. The company’s stock had a trading volume of 11,500 shares, compared to its average volume of 52,740. Aileron Therapeutics has a fifty-two week low of $9.58 and a fifty-two week high of $15.48.

Several large investors have recently made changes to their positions in the company. California State Teachers Retirement System purchased a new position in shares of Aileron Therapeutics in the third quarter worth about $110,000. Vanguard Group Inc. purchased a new position in shares of Aileron Therapeutics in the second quarter worth about $111,000. Tudor Investment Corp ET AL purchased a new position in shares of Aileron Therapeutics in the second quarter worth about $112,000. Bank of New York Mellon Corp purchased a new position in shares of Aileron Therapeutics in the third quarter worth about $135,000. Finally, Schwab Charles Investment Management Inc. purchased a new position in shares of Aileron Therapeutics in the third quarter worth about $165,000. Hedge funds and other institutional investors own 12.39% of the company’s stock.

Aileron Therapeutics Company Profile

Aileron Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing a class of therapeutics called stapled peptides. It is also developing a pipeline of stapled peptide drugs across a range of therapeutic areas, including cancer, endocrine and metabolic diseases and inflammation.

Earnings History and Estimates for Aileron Therapeutics (NASDAQ:ALRN)

Receive News & Ratings for Aileron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.